Liu David R.

10% owner Liu buys 21,000 PRME shares at $2.52; stock now $2.73, -59.2% from 52-week high

Liu David R., a 10% owner of Prime Medicine, Inc., purchased 21,000 shares at $2.52 on 2025-06-30, increasing holdings from 20,219,945 to 20,240,945 shares. The company is unprofitable with net income of $-51,890,000.00 against revenue of $1,454,000.00 in its latest quarter, and the stock trades $2.73 (current) versus a 52-week high of $6.70, representing a -59.2% decline from peak. Within a 7-day window (2025-06-23 through 2025-06-30), Liu executed three consecutive buy transactions at PRME, each outcome remaining unmeasurable at both 30-day and 90-day horizons due to recency. Cross-ticker, Liu's track record shows 3 prior open-market buys but no documented well-timed outcomes at the 90-day mark.

10% owner Liu David R. buys 21,000 shares of PRME at $2.16; third consecutive buy in 9 days amid -67.8% drawdown from 52-week high.

Liu David R., a 10% shareholder, purchased 21,000 shares at $2.16 on 2025-06-23, representing a net increase of 21,000 shares (+0.1% vs pre-transaction holdings of 20.20M shares). This transaction is noteworthy as the third open-market buy by this insider at PRME within 9 calendar days (prior buys on 2025-06-16 and 2025-06-11). The purchase occurs at a price that is -67.8% below the 52-week high of $6.70, though the stock has recovered +67.4% over the preceding 30 days. The company remains unprofitable with net income of $-51.9M in its most recent full fiscal year and quarterly revenue of only $1.5M, presenting a context of financial distress despite the recent price rebound. The rapid sequence of accumulation by a major shareholder warrants attention to whether the insider views the recent 30-day appreciation as a sustained recovery or a tactical entry point in a deeply distressed biotech.

10% owner Liu David R. bought 21,000 shares of PRME at $1.49 on 2025-06-16, days after prior $1.49 purchase; stock -81.0% from 52-week high despite $196.9M market cap.

Liu David R., a 10% owner, purchased 21,000 shares at $1.49 on 2025-06-16, his second open-market buy in six days at the same price (prior buy on 2025-06-11 at PRME). The stock has deteriorated significantly, trading -81.0% from its 52-week high of $7.90 and down 5.7% over 30 days and 14.8% over 90 days. The company is fundamentally challenged: it reported revenue of $1,454,000.00 in its latest quarter against a net loss of $-51,890,000.00, and was unprofitable over its most recent full fiscal year. The rapid succession of purchases at an identical price point in a declining stock warrants attention to the underlying business trajectory and the owner's assessment of value at these levels.

10% owner Liu David R. acquired 21,000 shares of PRME at $1.60, stock now $1.46 (-81.5% from 52-week high)

Liu David R., a 10% owner of Prime Medicine, purchased 21,000 shares at $1.60 on 2025-06-11, increasing holdings to 20.18M shares. The stock has declined significantly, trading 81.5% below its 52-week high of $7.90, though it has recovered 15.0% over the past 30 days. The company reported a net loss of $51.9M against quarterly revenue of $1.5M, indicating a deeply unprofitable operation with a market cap of $191.7M. This buy by a major shareholder during a period of substantial stock weakness and ongoing losses warrants scrutiny of whether this reflects conviction in a turnaround or represents accumulation at an inflated valuation relative to fundamentals.